KROS — Keros Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1664710 ·
Last close
$11.31
Market Cap
$221.95M
52W High
$22.55
52W Low
$8.98
ADV30
194,517
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 40,009,000 — 12,818,000 14,153,000 307,371,000 259,464,000 28,273,000
Jun 2026 0 — -30,937,000 -28,710,000 287,600,000 257,606,000 25,280,000
Mar 2026 367,000 — -25,877,000 -23,708,000 312,293,000 281,497,000 26,663,000
Dec 2025 385,000 — -29,270,000 -23,461,000 338,021,000 287,415,000 34,889,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-47,993,000
Investing CF
$-494,000
Financing CF
$-384,122,000
CapEx
$-494,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.70
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-534,183,000
Inventory
—
Receivables
$2,757,000
ST Investments
—
EBIT TTM
$-101,468,000
Pretax Income TTM
$-86,097,000
Interest Exp TTM
—
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$40,761,000
EBITDA
$-68,677,000
Free Cash Flow
$-24,998,250
Enterprise Value
$-60,669,860
Total Cash
$259,464,000
Total Debt
$15,110,000
Shares Out
19,624,374
Trailing EPS
$-2.32
Book Value
$14.07
ROE
-12.6%
ROA
-8.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 244,061,000 67,569,000 87,014,000 338,021,000 34,889,000 303,132,000 107,505,000
Dec 2024 3,550,000 -209,595,000 -187,353,000 615,886,000 44,333,000 571,553,000 -160,869,000
Dec 2023 151,000 -167,541,000 -152,992,000 370,025,000 37,812,000 332,213,000 -124,508,000
Dec 2022 0 -107,709,000 -104,679,000 306,781,000 29,358,000 277,423,000 -70,062,000

TTM Snapshot

Revenues TTM
$15,014,000
NetIncome TTM
$-83,159,000
OpCashFlow TTM
—
Assets (Latest)
$287,600,000
Forward EPS
$-6.62

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $12.50 · spot: $12.00 · call volume: 23 · put volume: 9
Expected Move to 2026-12-18: ±$2.67 (22.29%) — implied range $9.32 – $14.68 · ATM straddle on $12.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IMRX Immuneering Corp $224.08M $3.46 —
PRLD Prelude Therapeutics Inc $216.05M $3.32 —
ARCT Arcturus Therapeutics Holdings Inc. $229.72M $7.97 —
VNDA Vanda Pharmaceuticals Inc. $230.39M $3.81 —
LAB STANDARD BIOTOOLS INC. $212.95M $0.54 —

News headlines (Yahoo Finance, 1h cache)

Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization
2026-11-16 21:01 · Yahoo
Down 21% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround
2026-11-10 13:35 · Yahoo
Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass Estimates
2026-11-05 21:45 · Yahoo
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results
2026-11-05 21:01 · Yahoo
Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage
2026-10-22 23:04 · Yahoo
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
2026-10-20 12:59 · Yahoo
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
2026-09-28 12:00 · Yahoo
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
2026-09-02 15:30 · Yahoo
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?
2026-08-14 23:37 · Yahoo
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
2026-07-30 20:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.